PCO371

Nomen chemicum:

1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]dec-1-en-8-yl )sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione

SMILES Code:

O=C1NC(C(C)(C)N1C2=CC(C)=C(CCS(=O)(N(CC3)CCC3(N=C(C4=CC=C(OC(F)F)F )C=C4)N5)C5=O)C(C)=C2)=O*

InChi Code:

InChI=1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44( 41,42) 36-12-10-28 (11) -13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30,31)32/h5-8,15-16H,9; -14H2,1-4H3,(H,33,35,39)(H,34,38,40)

InChi Key:

LDZJFVOUPUFOHX-UHFFFAOYSA-N

Keyword:

PCO371; PCO-371; PCO 371

Solubilitas: 

Repono: 

Descriptio:

PCO371 potens et selectiva PTHR1 agonist ad tractationem hypoparathyroidismi. Administratio oralis PCO371 ad mures osteopenicae in osseo turnoveri notabili incremento cum massa ossis limitata auctum provocat. In muribus hypocalcemicis, PCO371 reducit serum calcii gradus sine calcii urinarii augmento, et effectibus fortioribus et diuturnis quam PTH injectionibus.

Target: PTHR1